Comprehensive Stock Comparison
Compare Unicycive Therapeutics, Inc. (UNCY) vs Apple Inc. (AAPL) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | AAPL | 6.4% revenue growth vs UNCY's -100.0% |
| Value | UNCY | Lower P/E (1.0x vs 31.1x) |
| Stability / Safety | UNCY | Beta 0.81 vs AAPL's 1.28, lower leverage |
| Dividends | UNCY | 2.4% yield, 1-year raise streak, vs AAPL's 0.4% |
| Momentum (1Y) | UNCY | +26.0% vs AAPL's +9.7% |
| Efficiency (ROA) | AAPL | 31.1% ROA vs UNCY's -66.0% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. It generates revenue primarily through research collaborations and licensing agreements — with no commercial products yet — while advancing its lead candidates through clinical trials. The company's competitive advantage lies in its specialized focus on kidney disease therapeutics and proprietary drug development platforms targeting unmet medical needs in nephrology.
Apple is a technology giant that designs and sells premium consumer electronics — most famously the iPhone — along with related software and services. It generates revenue primarily from hardware sales (roughly 80% of total) and a fast-growing services segment (around 20%) that includes the App Store, subscriptions, and licensing. Its key competitive advantage is a powerful ecosystem that locks users into its hardware, software, and services through seamless integration and high switching costs.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
UNCY leads in 2 of 6 categories (Financial Metrics, Valuation Metrics). AAPL leads in 2 (Profitability & Efficiency, Total Returns). 2 tied.
Financial Metrics (TTM)
AAPL and UNCY operate at a comparable scale, with $435.6B and $0 in trailing revenue.
| Metric | UNCYUnicycive Therape… | AAPLApple Inc. |
|---|---|---|
| RevenueTrailing 12 months | $0 | $435.6B |
| EBITDAEarnings before interest/tax | -$31M | $152.9B |
| Net IncomeAfter-tax profit | -$33M | $117.8B |
| Free Cash FlowCash after capex | -$30M | $123.3B |
| Gross MarginGross profit ÷ Revenue | — | +47.3% |
| Operating MarginEBIT ÷ Revenue | — | +32.4% |
| Net MarginNet income ÷ Revenue | — | +27.0% |
| FCF MarginFCF ÷ Revenue | — | +28.3% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +15.7% |
| EPS Growth (YoY)Latest quarter vs prior year | +28.3% | +18.3% |
Valuation Metrics
| Metric | UNCYUnicycive Therape… | AAPLApple Inc. |
|---|---|---|
| Market CapShares × price | $144M | $3.88T |
| Enterprise ValueMkt cap + debt − cash | $119M | $3.97T |
| Trailing P/EPrice ÷ TTM EPS | -1.24x | 35.41x |
| Forward P/EPrice ÷ next-FY EPS est. | 1.01x | 31.15x |
| PEG RatioP/E ÷ EPS growth rate | — | 1.98x |
| EV / EBITDAEnterprise value multiple | — | 27.45x |
| Price / SalesMarket cap ÷ Revenue | — | 9.33x |
| Price / BookPrice ÷ Book value/share | 6.25x | 53.76x |
| Price / FCFMarket cap ÷ FCF | — | 39.33x |
Profitability & Efficiency
AAPL delivers a 133.5% return on equity — every $100 of shareholder capital generates $134 in annual profit, vs $-89 for UNCY. UNCY carries lower financial leverage with a 0.10x debt-to-equity ratio, signaling a more conservative balance sheet compared to AAPL's 1.67x. On the Piotroski fundamental quality scale (0–9), AAPL scores 7/9 vs UNCY's 4/9, reflecting strong financial health.
| Metric | UNCYUnicycive Therape… | AAPLApple Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -89.1% | +133.5% |
| ROA (TTM)Return on assets | -66.0% | +31.1% |
| ROICReturn on invested capital | — | +64.5% |
| ROCEReturn on capital employed | -15.3% | +69.6% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 7 |
| Debt / EquityFinancial leverage | 0.10x | 1.67x |
| Net DebtTotal debt minus cash | -$25M | $89.7B |
| Cash & Equiv.Liquid assets | $26M | $33.5B |
| Total DebtShort + long-term debt | $773,000 | $123.3B |
| Interest CoverageEBIT ÷ Interest expense | -335.02x | — |
Total Returns (with DRIP)
A $10,000 investment in AAPL five years ago would be worth $21,049 today (with dividends reinvested), compared to $1,386 for UNCY. Over the past 12 months, UNCY leads with a +26.0% total return vs AAPL's +9.7%. The 3-year compound annual growth rate (CAGR) favors AAPL at 21.9% vs UNCY's 10.3% — a key indicator of consistent wealth creation.
| Metric | UNCYUnicycive Therape… | AAPLApple Inc. |
|---|---|---|
| YTD ReturnYear-to-date | +19.5% | -2.4% |
| 1-Year ReturnPast 12 months | +26.0% | +9.7% |
| 3-Year ReturnCumulative with dividends | +34.0% | +81.2% |
| 5-Year ReturnCumulative with dividends | -86.1% | +110.5% |
| 10-Year ReturnCumulative with dividends | -86.1% | +1027.4% |
| CAGR (3Y)Annualised 3-year return | +10.3% | +21.9% |
Risk & Volatility
UNCY is the less volatile stock with a 0.81 beta — it tends to amplify market swings less than AAPL's 1.28 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AAPL currently trades 91.5% from its 52-week high vs UNCY's 63.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | UNCYUnicycive Therape… | AAPLApple Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.81x | 1.28x |
| 52-Week HighHighest price in past year | $11.00 | $288.61 |
| 52-Week LowLowest price in past year | $3.71 | $169.21 |
| % of 52W HighCurrent price vs 52-week peak | +63.0% | +91.5% |
| RSI (14)Momentum oscillator 0–100 | 56.2 | 57.5 |
| Avg Volume (50D)Average daily shares traded | 474K | 40.9M |
Analyst Outlook
Wall Street rates UNCY as "Buy" and AAPL as "Buy". For income investors, UNCY offers the higher dividend yield at 2.36% vs AAPL's 0.39%.
| Metric | UNCYUnicycive Therape… | AAPLApple Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | — | $303.11 |
| # AnalystsCovering analysts | 5 | 109 |
| Dividend YieldAnnual dividend ÷ price | +2.4% | +0.4% |
| Dividend StreakConsecutive years of raises | 1 | 14 |
| Dividend / ShareAnnual DPS | $0.16 | $1.03 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +2.3% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Jul 21 | Feb 26 | Change |
|---|---|---|---|
| Unicycive Therapeut… (UNCY) | 100 | 12.9 | -87.1% |
| Apple Inc. (AAPL) | 100 | 185.55 | +85.5% |
Apple Inc. (AAPL) returned +110% over 5 years vs Unicycive Therapeut… (UNCY)'s -86%. A $10,000 investment in AAPL 5 years ago would be worth $21,049 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Unicycive Therapeut… (UNCY) | $0.00 | $0.00 | — |
| Apple Inc. (AAPL) | $215.6B | $416.2B | +93.0% |
Apple Inc.'s revenue grew from $215.6B (2016) to $416.2B (2025) — a 7.6% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Unicycive Therapeut… (UNCY) | -19.0% | -45.3% | -138.3% |
| Apple Inc. (AAPL) | 21.2% | 26.9% | +27.0% |
Apple Inc.'s net margin went from 21% (2016) to 27% (2025).
Chart 4P/E Ratio History — 9 Years
| Stock | 2017 | 2025 | Change |
|---|---|---|---|
| Apple Inc. (AAPL) | 18.4 | 36.4 | +97.8% |
Apple Inc. has traded in a 13x–41x P/E range over 9 years; current trailing P/E is ~35x.
Chart 5EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Unicycive Therapeut… (UNCY) | -0.14 | -5.6 | -3900.0% |
| Apple Inc. (AAPL) | 2.08 | 7.46 | +258.7% |
Apple Inc.'s EPS grew from $2.08 (2016) to $7.46 (2025) — a 15% CAGR.
Chart 6Free Cash Flow — 5 Years
Unicycive Therapeutics, Inc. generated $-29M FCF in 2024 (-394% vs 2021). Apple Inc. generated $99B FCF in 2025 (+6% vs 2021).
UNCY vs AAPL: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is UNCY or AAPL a better buy right now?
Apple Inc. (AAPL) offers the better valuation at 35.4x trailing P/E (31.1x forward), making it the more compelling value choice. Analysts rate Unicycive Therapeutics, Inc. (UNCY) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — UNCY or AAPL?
On forward P/E, Unicycive Therapeutics, Inc. is actually cheaper at 1.0x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — UNCY or AAPL?
Over the past 5 years, Apple Inc. (AAPL) delivered a total return of +110.5%, compared to -86.1% for Unicycive Therapeutics, Inc. (UNCY). A $10,000 investment in AAPL five years ago would be worth approximately $21K today (assuming dividends reinvested). Over 10 years, the gap is even starker: AAPL returned +1027% versus UNCY's -86.1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — UNCY or AAPL?
By beta (market sensitivity over 5 years), Unicycive Therapeutics, Inc. (UNCY) is the lower-risk stock at 0.81β versus Apple Inc.'s 1.28β — meaning AAPL is approximately 58% more volatile than UNCY relative to the S&P 500. On balance sheet safety, Unicycive Therapeutics, Inc. (UNCY) carries a lower debt/equity ratio of 10% versus 167% for Apple Inc. — giving it more financial flexibility in a downturn.
05Which has better profit margins — UNCY or AAPL?
Apple Inc. (AAPL) is the more profitable company, earning 26.9% net margin versus 0.0% for Unicycive Therapeutics, Inc. — meaning it keeps 26.9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AAPL leads at 32.0% versus 0.0% for UNCY. At the gross margin level — before operating expenses — AAPL leads at 46.9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is UNCY or AAPL more undervalued right now?
On forward earnings alone, Unicycive Therapeutics, Inc. (UNCY) trades at 1.0x forward P/E versus 31.1x for Apple Inc. — 30.1x cheaper on a one-year earnings basis.
07Which pays a better dividend — UNCY or AAPL?
All stocks in this comparison pay dividends. Unicycive Therapeutics, Inc. (UNCY) offers the highest yield at 2.4%, versus 0.4% for Apple Inc. (AAPL).
08Is UNCY or AAPL better for a retirement portfolio?
For long-horizon retirement investors, Unicycive Therapeutics, Inc. (UNCY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.81), 2.4% yield). Both have compounded well over 10 years (UNCY: -86.1%, AAPL: +1027%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between UNCY and AAPL?
These companies operate in different sectors (UNCY (Healthcare) and AAPL (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced. UNCY pays a dividend while AAPL does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.